Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.25
Bid: 6.00
Ask: 6.50
Change: 0.00 (0.00%)
Spread: 0.50 (8.333%)
Open: 6.25
High: 6.25
Low: 6.25
Prev. Close: 6.25
VRCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2022 18:12

RNS Number : 8251F
Verici Dx PLC
23 March 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0000654321

Issuer Name

VERICI DX PLC

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights; An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Icahn School of Medicine at Mount Sinai

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Mar-2022

6. Date on which Issuer notified

23-Mar-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

11.400000

0.000000

11.400000

19501330

Position of previous notification (if applicable)

13

13

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BM8HZD43

19501330

0

11.400000

0.000000

Sub Total 8.A

19501330

11.400000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

23-Mar-2022

13. Place Of Completion

USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFLTVLIVFIF
Date   Source Headline
27th Feb 20232:00 pmRNSPrice Monitoring Extension
7th Dec 20227:00 amRNSDirector/PDMR Shareholding
1st Dec 20226:07 pmRNSCorrection: Holding(s) in Company
3rd Oct 20227:00 amRNSProduct rebranding as Tutivia™
7th Sep 20227:00 amRNSHalf-year Report
6th Sep 20227:00 amRNSPositive results for Clarava from validation study
5th Sep 20227:00 amRNSNotice of Results
2nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20224:35 pmRNSPrice Monitoring Extension
27th Jun 20223:17 pmRNSResult of AGM and voting results
24th Jun 20227:00 amRNSHolding(s) in Company
20th Jun 20227:30 amRNSDistribution of Verici Dx shares by EKF
16th Jun 20227:00 amRNSInvestor Presentation
15th Jun 202210:57 amRNSCEO Video Interview
14th Jun 20229:00 amRNSFurther data from Tuteva™ validation study
9th Jun 20227:00 amRNSCommercial Team Appointments
25th May 202212:00 pmRNSPosting of Annual Report & Accounts
19th May 20227:00 amRNSFinal Results
12th May 20227:00 amRNSResults of Tuteva™ clinical validation study
1st Apr 20227:00 amRNSClinical Validation Study Update
23rd Mar 20226:12 pmRNSHolding(s) in Company
21st Mar 20227:00 amRNSHolding(s) in Company
18th Mar 20225:13 pmRNSHolding(s) in Company
16th Mar 20223:33 pmRNSHolding(s) in Company
15th Mar 20224:34 pmRNSHolding(s) in Company
11th Mar 20229:30 amRNSClose of Subscription and Fundraise Update
4th Mar 20224:13 pmRNSResult of Fundraise
4th Mar 202212:20 pmRNSClose of Accelerated Bookbuild
4th Mar 20227:10 amRNSProposed Fundraise
15th Feb 20227:00 amRNSSuccessful completion of analytical validation
26th Jan 20224:28 pmRNSNet Asset Value(s)
14th Jan 20227:00 amRNSInvestor Presentation
12th Jan 20222:00 pmRNSProgress and strategy update
6th Jan 20227:00 amRNSClarava™ and Tuteva™ complete testing requirements
5th Jan 20227:00 amRNSCollaboration with Illumina
4th Jan 20227:00 amRNSGrant of two CPT Codes by AMA
17th Dec 20211:19 pmRNSHolding(s) in Company
8th Nov 20217:00 amRNSLaunch of Barbara T. Murphy Endowed Lectureship
1st Nov 20217:00 amRNSLaunch of Career Development Research Grant
13th Sep 20217:01 amRNSLorenzo Gallon, MD, Appointed as Chair of S.A.B
13th Sep 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSPatient enrolment completed
19th Aug 20217:00 amRNSAppointment of Non-executive Director
27th Jul 20217:00 amRNSAcceptance to CLIA Program
20th Jul 20217:00 amRNSFirst European Clinical Trial Site Initiated
1st Jul 20214:56 pmRNSDirectorate Change
24th Jun 20217:00 amRNSNon-executive Director receives award
26th May 20214:41 pmRNSSecond Price Monitoring Extn
26th May 20214:35 pmRNSPrice Monitoring Extension
19th May 20213:14 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.